Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 3
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07080658Phase 1Completed

[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants

Role: lead

NCT06205329Phase 1Completed

Study of WPV01 in Healthy Subjects

Role: lead

NCT06197217Phase 3Completed

Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19

Role: lead

NCT05752175Phase 2Completed

Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection

Role: lead

All 4 trials loaded